€1.45 million grant from EIC-Transition!

We are pleased to announce that we have been granted €1.45 million from the EIC-Transition to bring our hiPSC-3D cardiac strips into a high throughput setting. In this project, we will miniaturize,  automate and scale-up the production of human 3D cardiac strips by combining 3D cardiac tissues derived from human induced pluripotent stem cell (hiPSC) with microfluidic technology of TOP platform, to generate a functional, high throughput 3D cardiac strips assay suitable for large scale drug screening.

Exciting new developments in our technology!

River BioMedics is a drug discovery company that leverages highly predictive human 3D cardiac models for target validation and drug screening for cardiovascular disease.